Long-Term Clinical Outcomes in HCV Genotype 1-Infected Patients Receiving Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir +/- Ribavirin: First interim Safety and Efficacy Results from TOPAZ-I
Schott, Eckart; Agarwal, Kosh; Dumas, Emily O.; Gaeta, Giovanni B.; Lee, Sam; Streinu-Cercel, Adrian; Andrade, Raul J.; Perez, Alma M.; George, Jacob; Bakulin, Igor G.; Marinho, Rui T.; Charafeddine, Mariem; Liu, Li; Pilot-Matias, Tami; Howieson, Kevin; Co, Melannie; Cohen, Daniel E.; Zoulim, Fabien; Ozaras, Resat